NASDAQ We note that edaravone injection (Bicun and Yidasheng) generated sales of RMB 702.7 million of sales in 2012, down 8.9% due to the loss of tenders. Earlier in the month, Simcere entered into a strategic agreement with Bristol-Myers Squibb Company ( BMY ...
Asian Scientist Magazine Boda is the manufacturer of Yidasheng, an injectable edaravone drug for management of stroke. Simcere announced on June 24 that it entered into a share transfer agreement with Zhuhai Rongding Equity Investment Partnership L.P. on June 17 to sell ... and more »
Seeking Alpha Both Boda and Simcere produce injectible edaravone drugs that act as neuroprotectives following a stroke. The Boda sale has taken place after Simcere's Chairman offered $503 million to take Simcere private, and the $65 million in sale proceeds will ...
